`U.S. Patent No. 7,049,328
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`TARO PHARMACEUTICALS U.S.A., INC.,
`Petitioner,
`
`v.
`
`APOTEX TECHNOLOGIES, INC.,
`Patent Owner.
`________________
`
`Case IPR2017-01446
`U.S. Patent No. 7,049,328
`
`Title: USE FOR DEFERIPRONE
`________________
`
`
`PATENT OWNER’S OBJECTIONS TO EVIDENCE IN
`PETITIONER’S REPLY PURSUANT TO 37 C.F.R. § 42.64
`
`
`
`
`
`IPR2017-01446
`U.S. Patent No. 7,049,328
`
`
`Pursuant to 37 C.F.R. § 42.64 and the Federal Rules of Evidence, as applied
`
`by the Board, Patent Owner Apotex Technologies, Inc. (“Apotex”) provides the
`
`following objections to Exhibits submitted by Taro Pharmaceuticals USA, Inc.
`
`(“Taro” or “Petitioner”) in association with its filing of its Reply (Paper 41). These
`
`objections are timely served within five (5) business days of Petitioner’s Reply.
`
`Apotex serves Taro with these objections to provide notice that Apotex may
`
`move to exclude the challenged evidence under 37 C.F.R. § 42.64(c) unless Taro
`
`cures the defects associated with the challenged evidence identified below. In
`
`addition, Apotex reserves the right to present further objections to this or additional
`
`evidence submitted by Taro, as allowed by the applicable rules or other authority.
`
`I.
`
`Exhibits 1037, 1038, 1040-1043, 1045, and 1047-1049
`
`Apotex objects to Exhibits 1037, 1038, 1040-1043, 1045, and 1047-1049 as
`
`hearsay. See Fed. R. Evid. 801, 802.
`
`Apotex object to Exhibits 1037, 1038, 1040-1043, 1045, and 1047-1049 for
`
`lack of authentication. See Fed. R. Evid. 901.
`
`Further, Apotex objects to the relevance and probative value of Exhibits
`
`1037, 1038, 1040-1043, 1045, and 1047-1049 as these exhibits do not contain
`
`evidence that is contradictory to any position advanced by Apotex in this
`
`proceeding. See Fed. R. Evid. 401, 402, and 403.
`
`1
`
`
`
`II. Exhibit 1060
`
`Apotex objects to portions of Exhibit 1060, Expert Declaration of Dr. Jayesh
`
`Mehta In Support of Petitioner’s Reply. Specifically, Apotex objects to ¶¶ 5, 14-
`
`16, 18, 20, 21-23, 36, 38-41, and 45-46 as not based on sufficient facts or data, the
`
`product of reliable principles and methods, and/or reliable application of the
`
`principles of methods and facts. See Fed. R. Evid. 702, 703, 705, 403; 77 Fed.
`
`Reg. at 48,763; 37 C.F.R. § 42.65.
`
`Apotex objects to ¶¶ 44-45 of Exhibit 1060 as irrelevant as these paragraphs
`
`are not directly cited in the Reply. See Fed. R. Evid. 401, 402. Apotex further
`
`objects to Fn 1 and portions of ¶ 14 as irrelevant because they contain cites to
`
`Exhibit 1066, which is not cited in the Petitioner’s Reply (Paper 41). See Fed. R.
`
`Evid. 401, 402. Apotex further objects to Fn 3 and portions of ¶ 25 as irrelevant
`
`because they contain cites to Exhibit 1065, which is not cited in Petitioner’s Reply
`
`and which is inadmissible for the reasons discussed below. See Fed. R. Evid. 401,
`
`402. Apotex further objects to Fn 8 and portions of ¶ 28 as irrelevant because they
`
`contain cites to Exhibits 1063-1064, which are not cited in Petitioner’s Reply. See
`
`Fed. R. Evid. 401, 402.
`
`Apotex objects to ¶¶ 19-50 as testimony provided on a topic which the
`
`declarant is not qualified to opine. See Fed. R. Evid. 702 and 703.
`
`
`
`
`2
`
`
`
`III. Exhibit 1065
`
`
`
`Apotex objects to Exhibit 1065 for lack of authentication. See Fed. R. Evid.
`
`901. Apotex further objects to Exhibit 1065 because it is not a printed publication.
`
`See 35 U.S.C. § 311(b). Apotex also objects to Exhibit 1065 as irrelevant. See
`
`Fed. R. Evid. 401, 402.
`
`IV. Exhibits 1052-1054 and 1056
`
`
`
`Apotex objects to the relevance and probative value of Exhibits 1052-1054
`
`and 1056, which are not cited in Petitioner’s Reply (Paper 41) or the Expert
`
`Declaration of Dr. Jayesh Mehta In Support of Petitioner’s Reply (Ex. 1060). See
`
`Fed. R. Evid. 401, 402, and 403.
`
`V. Exhibits 1063-1066
`
`
`
`Apotex objects to the relevance and probative value of Exhibits 1063-1066,
`
`which are cited in the Expert Declaration of Dr. Jayesh Mehta In Support of
`
`Petitioner’s Reply (Ex. 1060), but not cited in Petitioner’s Reply (Paper 41). See
`
`Fed. R. Evid. 401, 402, and 403.
`
`
`
`
`
`
`
`
`
`Date: June 20, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
` By: W. Blake Coblentz
`
`W. Blake Coblentz
`
`Reg. No. 57,104
`
`COZEN O’CONNOR
`1200 Nineteenth Street, N.W.
`Washington, D.C. 20036
`(202) 912-4837
`
`
`
`
`3
`
`
`
`IPR2017-01446
`U.S. Patent No. 7,049,328
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on June 20, 2018, I caused a true and correct copy of
`
`Patent Owner’s Objections to Evidence in Petitioner’s Reply to be served via
`
`electronic mail on the following attorneys of record:
`
`Huiya Wu
`Sarah Fink
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`HWu@goodwin.law.com
`SFink@goodwinlaw.com
`
`
`
`
`
`
`
`Date: June 20, 2018
`
`
`
`/s/ W. Blake Coblentz
`W. Blake Coblentz
`Reg. No. 57,104
`COZEN O’CONNOR
`1200 Nineteenth Street, N.W.
`Washington, DC 20036
`(202) 912-4837
`
`
`
`
`
`